Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemosensitivity linked to p73 function.

Meredith S Irwin1, Keiichi Kondo, Maria Carmen Marin

  • 1Dana-Farber Cancer Institute and Brigham and Womens Hospital, Harvard Medical School, Boston, MA 02115, USA.

Cancer Cell
|May 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved Outcomes for Older Children, Adolescents, and Young Adults With Neuroblastoma in the Post-Immunotherapy Era: An Updated Report From the International Neuroblastoma Risk Group.

Pediatric blood & cancer·2026
Same author

A Quality Improvement Initiative to Standardize Pneumocystis jirovecii Pneumonia Prophylaxis in Pediatric Patients With Solid Tumors.

Pediatric blood & cancer·2026
Same author

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions.

Pediatric blood & cancer·2026
Same author

Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project.

Pediatric blood & cancer·2025
Same author

International neuroblastoma risk group consortium: a model of networking for rare cancers.

Journal of the National Cancer Institute·2025
Same journal

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis.

Cancer cell·2026
Same journal

Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption.

Cancer cell·2026
Same journal

Intratumoral B cells under stress.

Cancer cell·2026
Same journal

Chronic stress unleashes an intratumor phage-fibroblast-B cell circuit to promote tumor growth.

Cancer cell·2026
Same journal

Molecular phenotypes and spatial archetypes: A new framework for cancer-associated fibroblasts.

Cancer cell·2026
Same journal

OpenIO: An open framework for AI-native immunotherapy.

Cancer cell·2026
See all related articles

The p53 family member p73 is crucial for chemotherapy effectiveness in human tumor cells, even those with defective p53. Blocking p73 function causes chemoresistance, highlighting its role in cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Chemotherapy typically induces DNA damage, leading to p53 activation and apoptosis.
  • Understanding chemosensitivity in p53-defective tumors is critical for effective cancer treatment.
  • The role of p53 family members in chemotherapy response remains incompletely understood.

Purpose of the Study:

  • To investigate the role of the p53 family member p73 in determining chemotherapeutic efficacy.
  • To explore the relationship between p73 function and chemoresistance in human tumor cells.
  • To determine if p73 is a determinant of chemotherapy response, irrespective of p53 status.

Main Methods:

  • Induction of p73 by various chemotherapeutic drugs was assessed.
  • p73 function was blocked using dominant-negative mutants, siRNA, and homologous recombination.

Related Experiment Videos

  • Chemoresistance was evaluated in human tumor cells and engineered transformed cells.
  • The interaction between mutant p53 and p73 was investigated.

    • Main Results:

    • The p53 family member p73 is induced by a broad spectrum of chemotherapeutic agents.
    • Inhibition of p73 function resulted in chemoresistance in human tumor cells and engineered cells, independent of p53 status.
    • Mutant p53 was found to inactivate p73.
    • Downregulation of mutant p53 expression led to enhanced chemosensitivity.

    Conclusions:

    • p73 plays a significant role in mediating the response to chemotherapy.
    • p73 is a key determinant of chemotherapeutic efficacy in human cancers.
    • Targeting p73 may represent a novel strategy to overcome chemoresistance in tumors with defective p53.